SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

PMGC Holdings Inc.
Date: Sept. 24, 2025 · CIK: 0001840563 · Accession: 0000000000-25-010393

Regulatory Compliance Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-290428

Date
September 24, 2025
Author
Graydon Bensler
Form
UPLOAD
Company
PMGC Holdings Inc.

Letter

September 24, 2025 Graydon Bensler Chief Executive Officer, Chief Financial Officer and Director PMGC Holdings Inc. 120 Newport Center Drive, Ste. 249 Newport Beach, CA 92660 Re:PMGC Holdings Inc. Registration Statement on Form S-1 Filed September 22, 2025 File No. 333-290428 Dear Graydon Bensler: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Ross Carmel, Esq.

Show Raw Text
September 24, 2025
Graydon Bensler
Chief Executive Officer, Chief Financial Officer and Director
PMGC Holdings Inc.
120 Newport Center Drive, Ste. 249
Newport Beach, CA 92660
Re:PMGC Holdings Inc.
Registration Statement on Form S-1
Filed September 22, 2025
File No. 333-290428
Dear Graydon Bensler:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Ross Carmel, Esq.